Cargando…
Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update
Hepatocellular carcinoma (HCC) accounts for most liver cancers and represents one of the deadliest cancers in the world. Despite the global demand for liver cancer treatments, there remain few options available. The U.S. Food and Drug Administration (FDA) recently approved Lumoxiti, a CD22-targeting...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356171/ https://www.ncbi.nlm.nih.gov/pubmed/32575752 http://dx.doi.org/10.3390/biom10060934 |